Agenus, Inc (AGEN) - Long-Term Debt to Capital Coefficient

Agenus is rapidly scaling its development in the fight against colorectal tumors by creating new methods for immune stimulation. This price chart for Agenus (AGEN) reflects the asset's dynamics, where the indicator stands at 0.00, while the business relies on revenue from licensing unique antibody patents. These operations are complemented by strict adherence to bioethics and an ecological approach to laboratory waste recycling during drug production.

Agenus invests in the development of immuno-oncology drugs and vaccines, which requires significant capital expenditures during the clinical research phase. An analysis of long-term liabilities relative to equity allows for an assessment of financial leverage and the stability of the funding structure, while the trend of the long-term debt-to-equity ratio serves as an indicator of the balance between business expansion and the risk of over-indebtedness.